1Naghavi M,Libby P,Falk E,et al. From vulnerable plaque to vulnerable patient: a call for new definition and risk assessment strategies; part I [J]. Circulation, 2003,108 (14) : 1664-1672.
3Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events and azithromycin in male survivors of myocardial infarction[J]. Circulation, 1997,96(2) : 404-407.
4Von der Thusen JH, Kuiper J, van Berkel TJ, et al. Interleukins in atherosclerosis: molecular pathways and therapeutic potential[J]. Pharmacol Rev,2003,55(1): 133-166.
5Klouche M, Rose-John S, Sehmiedt W, et al. Enzymatically degraded, nonoxidized LDL Induces human vascular smooth muscle cell activation, foam cell transformation, and proliferation[J]. Circulation, 2000,101 (15) : 1799-1805.
6Haverkate F,Thompson SG,Pyke SD,et al. Production of Creactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group[J]. Lancet, 1997,349(9050) :462-466.
7Corsetti JP,Rainwater DL, Moss A J, et al. High lipoprotein- associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients[J]. Clin Chem, 2006,52(7) : 1331-1338.
8Serruys PW,Garcia-Garcia HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque [J]. Circulation, 2008,118(11):1172-1182.
9Blankenberg S, Rupprecht J, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase' 9 and prognosis of patients with cardiovascular disease[J]. Circulation, 2003, 107 (12) : 1579- 1585.
10Frey AW, Hodgson JM,Muller C, et al. Ultrasound-guided strategy for provisional stenting with focal balloon combination catheter: results from the randomized Strategy for Intracoronary Ultresound-guided PTCA and Stenting (SIPS) trial [J]. Circulation, 2000,102 (20) : 2497-2502.
二级参考文献8
1Lusis AJ. Atherosclerosis. Nature, 2000. 407: 233-241.
2Zhu J, Quyyumi AA, Norman JE, et al. The possible role of hepatitis A virus in the pathogenesis of atherosclerosis. J Infect Dis, 2000,182:1583-1587.
3Meier CR, Jick SS, Derby LE, et al. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet, 1998, 351:1467-1471.
4Epsein SE, Zhou YF, Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms. Circulation, 1999, 100:e20- e 28.
5Rupprecht HJ, Blankenberg S, Bickel C, et al. impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation, 2001,104:25-31.
6Zhu J, Quyyumi AA, Norman JE, et al. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol, 2000,85:140-146.
7Danesh J, Whincup P, Walker M, et al. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. BMJ, 2000, 321:208-213.
8Whincup P, Danesh J, Walker M, et al. Prospective study of potentially virulent strains of Helicobacter pylori and coronary heart disease in middle-aged men. Circulation, 2000,101:1647-1652.
8Naghavi M,Libby P,Falk E,et al.From vulnerable plaque to vulnerable patient:a call for new definitions and risk assessment strategies:Part Ⅰ[J].Circulation,2003,108(14):1664-1672.
9Schwartz SM,Galis ZS,Rosenfeld ME,et al.Plaque rupture in humans and mice[J].Arterioscler Thromb Vasc Biol,2007,27(4):705-713.
